Skip to main content
GALT
NASDAQ Life Sciences

Galectin Therapeutics Reports Q1 2026 Results, Extends Cash Runway to May 2027, Awaits Key FDA Meeting for Lead Drug

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.3
Mkt Cap
$154.694M
52W Low
$1.21
52W High
$7.13
52W Position info
90% above low
Off High info
68% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GALT sits 90% above its 52-week low of $1.21.

Summary

Galectin Therapeutics reported reduced Q1 2026 losses and cash burn, but faces ongoing liquidity challenges with a cash runway to May 2027, a persistent material weakness in financial controls, and a critical upcoming FDA meeting for its lead drug.


Key Events · Earnings and Guidance · GALT

  • Reduced Net Loss and Cash Burn

    The company reported a net loss of $5.046 million for Q1 2026, a significant improvement from $9.631 million in Q1 2025. Net cash used in operating activities decreased to $3.866 million from $7.689 million, primarily due to the completion of the NAVIGATE clinical trial.

  • Limited Cash Runway and Related-Party Dependence

    Cash and cash equivalents stood at $14.111 million as of March 31, 2026. Including a $10 million line of credit from its chairman, the company projects sufficient cash to fund operations only through May 2027. Future capital needs will require additional debt or equity financing.

  • Critical FDA Meeting for Lead Drug Belapectin

    Following mixed top-line results from the NAVIGATE trial (reported December 2024), which showed a 68.1% reduction in varices in a U.S. subgroup, the company requested and was granted an in-person Type C meeting with the FDA in Q2 2026 to discuss the path forward for belapectin.

  • Persistent Material Weakness in Internal Controls

    Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to a material weakness in the valuation of derivative liabilities on convertible notes, a weakness previously disclosed in the 2025 Annual Report on Form 10-K.


Analysis · GALT · Life Sciences

Galectin Therapeutics' latest quarterly report highlights a critical juncture for the clinical-stage biopharmaceutical company. While the net loss and cash used in operations decreased significantly due to the completion of its NAVIGATE clinical trial, the company's liquidity remains a primary concern, with a cash runway projected only through May 2027. The path forward for its lead drug, belapectin, hinges on an upcoming Type C meeting with the FDA in Q2 2026, following mixed top-line trial results that showed efficacy in a U.S. subgroup. The company also continues to report a material weakness in its internal controls over financial reporting, impacting the reliability of its financial statements.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GALT was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154.7M. The 52-week trading range was $1.21 to $7.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GALT - Latest Insights

GALT
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $2.97 info
Change: -$0.135 (-4%) info
Market Cap: $299.019M info
GALT
Nov 16, 2026, 7:50 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $2.97 info
Change: -$0.135 (-4%) info
Market Cap: $299.019M info
GALT
Oct 13, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $2.97 info
Change: -$0.975 (-25%) info
Market Cap: $299.019M info
GALT
Oct 02, 2026, 3:53 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $2.97 info
Change: -$0.950 (-24%) info
Market Cap: $299.019M info
GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $2.97 info
Change: -$0.485 (-14%) info
Market Cap: $299.019M info